ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

117
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Refresh
23 May 2024 17:09

Henlius (2696 HK): Privatisation by Fosun Pharma?

The shares are 62% below the IPO price. However, shareholders with blocking stakes would welcome an offer suggesting a 30-40% takeover premium...

Logo
358 Views
Share
23 May 2024 14:40

Henlius Biotech (2696 HK): Fosun Offer?

IF Fosun wants to take the company private, an Offer Price of $26/share, may get the job done. $30/share would be optically be more preferable.

Logo
349 Views
Share
25 Aug 2024 06:16

Weekly Deals Digest (25 Aug) - Seven & I, Iriso, Fancl, Alps Logistics, China TCM, Henlius, GA Pack

Last week, notable developments occurred in Event-Driven (Seven & I, Iriso, Fancl, Alps Logistics, China TCM, Henlius, GA Pack, APM) and ECM (99...

Logo
53 Views
Share
24 Aug 2024 15:00

(Mostly) Asia-Pac M&A: APM Human Services, TCM, Alps Logistics, Fancl, Jeisys Medical, PropertyGuru

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
152 Views
Share
19 Aug 2024 00:39

Merger Arb Mondays (19 Aug) - China TCM, Henlius, Canvest, CPMC, JTower, Fuji Soft PropertyGuru

This week, the highest gross spreads are HEC Pharma (114.4%), JTower (69.0%), China TCM (11.9%), Canvest (10.4%), Capitol (8.5%), Malaysia Airports...

Logo
229 Views
Share
x